BPC-157 Administration Routes in Research: Oral, Injectable, Nasal and Acetate vs Arginate

BPC-157 is sold in more forms than almost any other research peptide: acetate vials for reconstitution, capsules marketed as arginate, and nasal sprays with no matching literature at all. Buyers frequently ask which route the underlying studies actually used, and whether the acetate-versus-arginate distinction is chemistry or marketing. This article walks through the route-by-route evidence base, corrects a widely repeated citation error, and lays out what is and is not known about the two salt forms, strictly in a preclinical, research-use context.

Is BPC-157 orally active in research models?

The oral-activity claim around BPC-157 traces back to its origin story. Sikiric and colleagues first described BPC as a peptide isolated from human gastric juice in 1993, framing it around a "stomach as protective organ" hypothesis (PMID 8298609). A 2011 review by the same group states that BPC-157 remains stable in human gastric juice for more than 24 hours, an unusual property for a peptide, which typically degrades within minutes in that environment (PMID 21548867). That review also references the Croatian PL 14736 clinical development program for inflammatory bowel disease and discusses both peroral and parenteral therapy in that context.

Downstream of that stability finding, the rodent literature repeatedly uses oral dosing. Typical protocols cited in the field use drinking-water administration at roughly 10 micrograms per kilogram or 10 nanograms per kilogram per day, sometimes expressed as concentrations of 0.16 micrograms per milliliter down to 0.16 nanograms per milliliter in about 12 milliliters of water per rat per day. These are study-described animal protocols, not a human dosing reference.

What is genuinely missing is a validated human oral pharmacokinetic or efficacy dataset. Gastric stability in vitro and efficacy via rat drinking water do not, on their own, establish that an oral capsule behaves the same way in a human digestive tract. Extrapolating the rodent oral signal to humans is an evidence gap, not settled science, and should be treated that way in any research summary.

Which routes carry the actual efficacy and pharmacokinetic literature?

Injectable routes, intraperitoneal (IP) in most rodent efficacy work, plus intramuscular (IM), intravenous (IV) and subcutaneous (SC) in pharmacokinetic and some efficacy studies, account for the large majority of the published BPC-157 dataset.

Two representative Sikiric-group papers illustrate the pattern. In a rat Achilles tendon-to-bone healing model, BPC-157 was given intraperitoneally once daily at 10 micrograms, 10 nanograms, or 10 picograms per kilogram, starting 30 minutes after surgery, and it both promoted healing and opposed corticosteroid-induced impairment (PMID 16583442). In a rat ileoileal anastomosis model, the same IP dosing scheme improved surgical-healing outcomes, and the paper explicitly ties the peptide to the human IBD clinical codes PL-10, PLD-116 and PL14736 (PMID 17713731).

The only formal pharmacokinetic dataset for BPC-157 comes from a 2022 study in rats and beagle dogs using IV and IM dosing, single and repeated (PMID 36588717). Two findings from that paper matter for anyone thinking about route choice in a research context. First, elimination half-life was under 30 minutes in both species after IV or IM administration, a short window that is consistent with why almost every Sikiric-group protocol uses once-daily or more frequent dosing rather than infrequent dosing. Second, intramuscular bioavailability was strongly species-dependent: roughly 14 to 19 percent in rats versus roughly 45 to 51 percent in dogs, a reminder that pharmacokinetic parameters from one species do not transfer cleanly to another.

For laboratories running injectable-route protocols, standard bench practice is to reconstitute lyophilized BPC-157 with bacteriostatic water, swirl gently rather than shake, keep the reconstituted vial refrigerated, and use it within the vendor-stated window. No BPC-157-specific official reconstitution pH citation exists in the literature, so any pH claim should stay general and vendor-level rather than attributed to a specific study.

BPC-157regeneration

Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.

Bacteriostatic Wateraccessories

USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, ~pH 6) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.

Graduated Measuring Syringe 1 mL 31G x 6 mmaccessories

Sterile 1 mL graduated laboratory syringe with a 31G x 6 mm fine tip. Individually wrapped, latex-free, pyrogen-free, PVC-free, with a high-contrast 0.01 mL black scale for precise liquid measuring and transfer.

What about topical and "nasal" BPC-157?

Topical application has a real, if narrow, literature. In a mouse burn-wound study, BPC-157 applied as a cream directly to the wound, alongside a separate intraperitoneal arm, improved healing parameters including less inflammation, better collagen organization and greater wound-breaking strength, and it also reduced burn-associated gastric lesions (PMID 11718984). In a rat alkali-burn model, a topical hydrogel at 200, 400 or 800 nanograms per milliliter applied twice daily for 18 days accelerated wound closure to a degree comparable with bFGF, and in-vitro work in the same paper linked the effect to ERK1/2-mediated proliferation, migration and tube formation in endothelial cells, consistent with a pro-angiogenic mechanism (PMID 25995620).

Intranasal delivery is a different story, and this is the single most important correction in this article. A 1997 paper on capsaicin-induced rhinitis in rats is frequently cited online as evidence for intranasal BPC-157 (PMID 9065615). Reading the actual method matters here: BPC-157 itself was given intraperitoneally at 10 micrograms per kilogram or 10 nanograms per kilogram as pretreatment, and only the irritant, capsaicin, was sprayed into the nostril to induce the rhinitis model. This is a nasal-mucosa disease model using an intraperitoneal peptide, not a study of intranasal BPC-157 delivery or pharmacokinetics. No dedicated rodent PK or efficacy paper for nasally administered BPC-157 was located in this review. Nasal-spray BPC-157 products sold commercially are, at present, a format without a matching study base.

Acetate vs arginate: does the salt form matter?

BPC-157 is a synthetic 15-amino-acid sequence, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a free-peptide molecular weight of 1419.5 grams per mole and formula C62H98N16O22 (PubChem CID 9941957). The acetate salt is a real, independently registered form, C64H102N16O24, PubChem CID 155977614, CAS 1628202-19-6, and it is the form dissolved in saline in essentially every injectable rodent study cited above. A search of PubChem and CAS registries did not turn up an independently characterized, separately registered "arginate" salt of BPC-157. In the research-peptide market, arginate functions primarily as a label attached to oral capsule products, not as a pharmaceutical salt form with its own registry entry.

Because the active 15-amino-acid sequence is identical regardless of the counter-ion attached to it, the counter-ion itself is unlikely to change the peptide's pharmacological activity once it is in solution. What differs in practice is the marketed route: injectable vials are sold as acetate, while oral capsules and some nasal sprays are marketed under the arginate or other salt labels. That is a packaging and route distinction, not a demonstrated difference in the peptide's biological behavior.

The specific number that circulates most widely, that arginate delivers roughly 90 percent oral bioavailability versus roughly 3 percent for acetate, appears only in vendor and blog marketing content, sometimes vaguely attributed to unspecified patent data. No peer-reviewed study directly comparing acetate and arginate oral bioavailability was located, and no peer-reviewed study has measured an isolated arginate oral bioavailability figure at all. That figure should be treated as an unverified commercial claim rather than a citable fact, and it should not be repeated as if it were established pharmacology.

BPC-157 has never been approved by the FDA or EMA for any indication. The closest thing to a marketed drug was the Pliva-developed PL-10 / PLD-116 / PL 14736 program, which reached that single rectal PK study and reportedly a Phase II trial, neither fully published. On the US regulatory side, BPC-157 was added to FDA's Category 2 bulk drug substances list in September 2023, which blocked licensed compounding pharmacies from preparing it, citing insufficient human safety data rather than a documented toxicity finding. In February 2026, HHS signaled intent to reverse Category 2 restrictions for a batch of peptides, and BPC-157 was reported removed from Category 2 around April 2026. It is now one of seven peptides scheduled for review at the FDA's Pharmacy Compounding Advisory Committee meeting on July 23 to 24, 2026, with BPC-157 specifically on the July 23 agenda (docket FDA-2025-N-6895); we cover that hearing and its EU relevance in a companion piece, FDA PCAC Hearing July 2026. Removal from Category 2 is a change in a US compounding category, not an FDA approval, and it does not create a legal over-the-counter or supplement status anywhere. BPC-157 remains an unapproved drug and, on peptidesdirect.io, an EU research chemical only.

On safety, the rodent literature from the Sikiric group repeatedly reports no observed toxicity at the doses tested, typically in the picogram-to-microgram-per-kilogram range. That claim should be read with three caveats: it originates almost entirely from one overlapping set of authors rather than independent toxicology labs, no comprehensive peer-reviewed rodent toxicology package (LD50, chronic dosing, genotoxicity, reproductive toxicity) appears to exist in the indexed literature, and published human safety data is essentially limited to the single, never-fully-published rectal PK study above. FDA's stated 2023 rationale for Category 2 was the near-absence of human data, not a specific adverse-event signal. The honest summary is: no major toxicity signal in the existing rodent literature, but essentially no published human safety data, and no verification of any given vial beyond its vendor's own third-party CoA. On peptidesdirect.io, every BPC-157 batch carries a per-batch Janoshik lab report on the CoA page, and purity methodology is documented on /purity.

Healing & Regenerationregeneration

Tissue repair, wound healing, and recovery peptides

Frequently asked questions

This article discusses BPC-157 strictly as an unapproved research chemical. All routes, doses and salt forms described are drawn from published preclinical and limited human pilot literature, not recommendations for human use.